FDA Approves First Oral GLP-1 Weight Loss Pill: Wegovy

FDA Approval of Oral Wegovy

• FDA has approved the pill version of Novo Nordisk's Wegovy, marking a significant development as the first oral GLP-1 drug for weight loss.
• The pill contains semaglutide, the same active ingredient found in the weekly Wegovy injection, known for its appetite-suppressing properties.

Dosing, Pricing, and Efficacy

• The starting dose of 1.5 milligrams is expected to be available early next month at a cash price of $149 per month.
• In late-stage trials, patients using the highest dose of the pill achieved up to 16.6% body weight loss over 64 weeks.
• The drug is also approved to reduce the risk of heart attack, stroke, and death in obese adults with existing heart disease.

Doctor and Patient Perspectives

• While doctors note that the pill offers a convenient daily option, some suggest the medication might feel more intense as it hits the system all at once.
• Potential side effects are similar to the injection, including nausea and vomiting.
• For individuals who dislike injections or have a fear of needles, this oral option could be a game-changer.

Market Competition and Production

• Eli Lilly is expected to seek approval for its own GLP-1 pill by summer of next year.
• Novo Nordisk has increased production to avoid shortages, a problem encountered with the injectable version upon its release.
• The competition between Novo Nordisk and Eli Lilly is described as a "weight loss war".